Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Akebia Therapeutics, Inc. (AKBA)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 8-K | 10-Q | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | | | 39.2% | 67.3% | 71.8% | 78.9% | 81.4% |
| Gross profit | | | | 60.8% | 32.7% | 28.2% | 21.1% | 18.6% |
| Selling, general and administrative | | | | 56.7% | 79.5% | | 80.5% | 73.7% |
| Research and development | | | | 47.1% | 67.8% | 69.2% | 74.0% | 73.1% |
| General and administrative | | | | | | 21.0% | | |
| Depreciation | | | | 0.6% | 0.8% | 0.9% | 0.9% | 0.9% |
| EBITA | | | | -32.0% | -99.9% | -107.3% | -118.8% | -115.6% |
| Amortization of intangibles | | | | 12.1% | 16.2% | 16.9% | 16.3% | 14.1% |
| EBIT | | | | -44.2% | -116.1% | -124.2% | -135.1% | -129.7% |
| Pre-tax income | | | | -55.0% | -123.6% | -132.4% | -142.0% | -135.0% |
| Income taxes | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | | | | -55.0% | -123.6% | -132.4% | -142.0% | -135.0% |
|